Clinical Trial: NCT04951583
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma
Status:
UNKNOWNPhase:
Phase 2| Lead Sponsor: | Centre hospitalier de l'Université de Montréal (CHUM) |
| Information Provided By: | Centre hospitalier de l'Université de Montréal (CHUM) |
| Last Update Posted: | 2024-08-07 |
Study Overview
Brief Summary
The aim of this study is to assess the anti-tumor activity of FMT administered in combination with ICI therapy.
Official Title
Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-Small Cell Lung Cancer and Melanoma Treated With Immune Checkpoint Inhibitors.
Conditions
Non Small Cell Lung Cancer Metastatic, Advanced Melanoma
Intervention / Treatment
- Combination Product: FMT + ICI
Other Study ID Numbers
- 21.173
Start Date (Actual)
2021-11-16
Primary Completion Date (Estimated)
2024-09-01
Study Completion Date (Estimated)
2025-09-01
Enrollment (Actual)
45
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Centre hospitalier de l'Université de Montréal (CHUM) |
| Information Provided By: | Centre hospitalier de l'Université de Montréal (CHUM) |
| Last Update Posted: | 2024-08-07 |
Study Overview
Brief Summary
The aim of this study is to assess the anti-tumor activity of FMT administered in combination with ICI therapy.
Official Title
Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-Small Cell Lung Cancer and Melanoma Treated With Immune Checkpoint Inhibitors.
Conditions
Non Small Cell Lung Cancer Metastatic, Advanced Melanoma
Intervention / Treatment
- Combination Product: FMT + ICI
Other Study ID Numbers
- 21.173
Start Date (Actual)
2021-11-16
Primary Completion Date (Estimated)
2024-09-01
Study Completion Date (Estimated)
2025-09-01
Enrollment (Actual)
45
Study Type
Interventional
Phase
Phase 2